(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/112695 A3

(51) International Patent Classification[7]: A61K 31/05, 9/127, 9/14, 9/48

(21) International Application Number: PCT/US2004/016114

(22) International Filing Date: 20 May 2004 (20.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/472,144	20 May 2003 (20.05.2003)	US
60/472,299	20 May 2003 (20.05.2003)	US
60/472,188	20 May 2003 (20.05.2003)	US
60/472,282	20 May 2003 (20.05.2003)	US
60/472,008	20 May 2003 (20.05.2003)	US

(71) Applicants *(for all designated States except US)*: **ERIMOS PHARMACEUTICAL LLC** [US/US]; 9600 Bellaire Boulevard, Suite 228, Houston, Texas 77036 (US). **JOHNS HOPKINS UNIVERSITY** [US/US]; 720 Rutland Avenue, Baltimore, Maryland 21205 (US). **HELLER, Jonathan** [US/US]; 1406 Duplin Road, Raleigh, North Carolina 27607 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FRAZER, Neil** [GB/US]; 109 Greyfriars Lane, Cary, North Carolina 27511 (US). **CHANG, Chih-Chuan** [CN/US]; Department of Biology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218 (US). **LIN, Elaine** [CN/US]; NYU School of Medicine, 550 First Avenue, New York, New York 10016 (US). **HUANG, Ru Chih C.** [US/US]; Department of Biology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218 (US).

(74) Agents: **ROBINS, Roberta** et al.; Robins & Pasternak LLP, 1731 Embarcadero Road, Suite 230, Palo Alto, California 94303 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report: 7 April 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR DELIVERY OF CATECHOLIC BUTANES FOR TREATMENT OF OBESITY

(57) Abstract: The present invention provides kits, methods and compositions for the treatment of obesity. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment.

WO 2004/112695 A3